Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2017

Open Access 01-12-2017 | Research

Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS® to ASCQ-Me℠

Authors: San Keller, Manshu Yang, Marsha J. Treadwell, Kathryn L. Hassell

Published in: Health and Quality of Life Outcomes | Issue 1/2017

Login to get access

Abstract

Background

Sickle Cell Disease (SCD) causes profound suffering and decrements in daily functioning. Demand is growing for valid and reliable measures to systematically document these effects, particularly in adults. The Adult Sickle Cell Quality of Life Measurement System, ASCQ-Me℠, was developed for this purpose. ASCQ-Me℠ is one of four measurement systems housed within the Person–Centered Assessment Resource (PCAR), funded by the National Institutes of Health, to support clinical research. To help users select the best of these measures for adults with SCD, we evaluated and compared two PCAR systems: one designed to be “universally applicable” (the Patient-Reported Outcome Measurement Information System, PROMIS®) and one designed specifically for SCD (ASCQ-Me℠).

Methods

Respondents to PROMIS and ASCQ-Me questions were 490 adults with SCD from seven geographically-disbursed clinics within the US. Data were collected for six ASCQ-Me measures (Emotional Impact, Sleep Impact, Social Impact, Stiffness Impact, Pain Impact, SCD Pain Episode Frequency and Severity) and ten PROMIS measures (Pain Impact, Pain Behavior, Physical Functioning, Anxiety, Depression, Fatigue, Satisfaction with Discretionary Social Activities, Satisfaction with Social Roles, Sleep Disturbance, and Sleep-Related Impairment). Statistical analyses, including analysis of variance and multiple linear regression, were conducted to determine the sensitivity of measures to SCD severity. SCD severity was assessed via a checklist of associated treatments and conditions.

Results

For those with the most severe SCD, PROMIS scores showed worse health compared to the general population for nine of ten health domains: the magnitude of the difference ranged 0.5 to 1.1 standard deviation units. The PROMIS domains most severely affected were Physical Functioning and Pain (Impact and Behavior). Significant differences by tertile of the SCD-MHC were shown for most PROMIS short forms and all ASCQ-Me short and fixed forms. In most models, ASCQ-Me measures explained statistically significant unique variance in SCD-MHC scores complementary to that explained by corresponding PROMIS measures.

Conclusions

Study results supported the validity of both PROMIS and ASCQ-Me measures for use in adults with SCD. Compared to comparable PROMIS scores, most ASCQ-Me scores were better predictors of SCD disease severity, as measured by a medical history checklist. The clinical implications of these results require further investigation.
Literature
1.
2.
Treadwell MT, et al. Adult sickle cell quality of life measurement information system (ASCQ-Me): conceptual model based on review of the literature and formative research. Clin J Pain. 2013;30(10):902–14.CrossRef
3.
Keller SD, et al. Patient reports of health outcome for adults living with sickle cell disease: development and testing of ASCQ-Me item banks. Health Qual Life Outcomes. 2014;22:125.CrossRef
4.
N.I.H. Department of Health and Human Services, editor. RFA-CA-13-008: Person-centered outcomes research resource. 2013.
5.
Smith A, et al. News from the NIH: Person-centered outcomes measurement: NIH-supported measurement systems to evaluate self-assessed health, functional performance, and symptomatic toxicity. Transl Behav Med. 2016;6(3):470–74.
6.
Fries JF, Bruce B, Cella D. The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S53–7.PubMed
7.
8.
Cella D, et al. The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. Qual Life Res. 2007;16 Suppl 1:133–41.CrossRefPubMed
9.
Adler D. Developing the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care. 2007;45(5):S1–2.CrossRef
10.
Aisiku IP, et al. Comparisons of high versus low emergency department utilizers in sickle cell disease. Ann Emerg Med. 2009;53(5):587–93.CrossRefPubMed
11.
Brawley OW, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148(12):932–8. PMID: 18458271, Epub 2008 May 5.CrossRefPubMed
12.
DeBaun MR, Kirkman FJ. Central nervous system complications and management in sickle cell disease. Blood. 2016;127(7):829–38.
13.
14.
15.
Halasa NB, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(11):1428–33.CrossRefPubMed
16.
Yawn BP, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Jama. 2014;312(10):1033–48.CrossRefPubMed
17.
18.
Badawy SM, et al. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. 2016 Nov.;28 [Epub ahead of print].
19.
Beverung LM, et al. Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy. Am J Hematol. 2015;90(2):139–43.CrossRefPubMedPubMedCentral
20.
Bhatia M, et al. Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2015;21(4):666–72.CrossRefPubMed
21.
Kelly MJ, et al. Journeys to recovery study, HSCT-CHESS™ study. Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT). Pediatr Blood Cancer. 2012;59(4):725–31. Epub 2011 Dec 19.CrossRefPubMed
22.
Thornburg CD, et al. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hematol Oncol. 2011;33(4):251–4.CrossRefPubMedPubMedCentral
23.
Bjorner JB, et al. Developing tailored instruments: item banking and computerized adaptive assessment. Qual Life Res. 2007;16 Suppl 1:95–108.CrossRefPubMed
24.
Reeve BB, et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care. 2007;45(5 Suppl 1):S22–31.CrossRefPubMed
25.
Keller S, Yang M. Development of an "R"-Based Computer Adaptive Assessment of Health Based on Patient Reports of their Functioning and Wellbeing. Poster presented at: The 119th Annual American Psychological Association Convention; Aug 4-7 2011; Washington, D.C.
26.
Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27(3 Suppl):S217–32.CrossRefPubMed
27.
Kantz ME, et al. Methods for assessing condition-specific and generic functional status outcomes after total knee replacement. Med Care. 1992;30(5 Suppl):Ms240–52.PubMed
28.
Fried TR, et al. Views of older persons with multiple morbidities on competing outcomes and clinical decision-making. J Am Geriatr Soc. 2008;56(10):1839–44.CrossRefPubMedPubMedCentral
29.
Gliklich RE, Hilinski JM. Longitudinal sensitivity of generic and specific health measures in chronic sinusitis. Qual Life Res. 1995;4(1):27–32.CrossRefPubMed
30.
Rothrock NE, et al. Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol. 2010;63(11):1195–204.CrossRefPubMedPubMedCentral
31.
Weaver KE, et al. Mental and physical health-related quality of life among US cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;21(11):2108–17.CrossRef
32.
Bessette L, et al. Comparative responsiveness of generic versus disease-specific and weighted versus unweighted health status measures in carpal tunnel syndrome. Med Care. 1998;36(4):491–502.CrossRefPubMed
33.
Wong CK, et al. Condition-specific measure was more responsive than generic measure in colorectal cancer: all but social domains. J Clin Epidemiol. 2013;66(5):557–65.CrossRefPubMed
34.
Walsh TL, et al. Is a condition-specific instrument for patients with low back pain/leg symptoms really necessary? The responsiveness of the Oswestry Disability Index, MODEMS, and the SF-36. Spine (Phila Pa 1976). 2003;28(6):607–15.
35.
Papuga MO, et al. Validation of GAITRite and PROMIS as high-throughput physical function outcome measures following ACL reconstruction. J Orthop Res. 2014;32(6):793–801.CrossRefPubMedPubMedCentral
36.
37.
Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine (Phila Pa 1976). 1983;8(2):141–4.CrossRef
38.
Ren XS, et al. The role of generic and disease-specific measures of physical and role functioning in assessing patient outcomes: a longitudinal study. J Ambul Care Manage. 2005;28(2):157–66.CrossRefPubMed
39.
40.
41.
Sprangers MA, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756–68.CrossRefPubMed
42.
de Boer AG, et al. Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry. 1996;61(1):70–4.CrossRefPubMedPubMedCentral
43.
Marks GB, Dunn SM, Woolcock AJ. A scale for the measurement of quality of life in adults with asthma. J Clin Epidemiol. 1992;45(5):461–72.CrossRefPubMed
44.
Duncan PW, et al. The stroke impact scale version 2.0: evaluation of reliability, validity, and sensitivity to change. Stroke. 1999;30(10):2131–40.CrossRefPubMed
45.
Hung M, et al. New paradigm for patient-reported outcomes assessment in foot & ankle research: computerized adaptive testing. Foot Ankle Int. 2012;33(8):621–6.CrossRefPubMed
46.
Olino TM, et al. Comparisons across depression assessment instruments in adolescence and young adulthood: an item response theory study using two linking methods. J Abnorm Child Psychol. 2013;41(8):1267–77.CrossRefPubMedPubMedCentral
47.
Rose M, et al. Evaluation of a preliminary physical function item bank supported the expected advantages of the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol. 2008;61(1):17–33.CrossRefPubMed
48.
Choi SW, et al. Efficiency of static and computer adaptive short forms compared to full-length measures of depressive symptoms. Qual Life Res. 2010;19(1):125–36.CrossRefPubMed
49.
Bender MA, Seibel GD. Sickle cell disease. 2003, Sep 15 [updated 2014 Oct23] In: Pagan RA, et al. editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016.
50.
Steinberg MH. Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches. Scientific World J. 2008;25(8):1295–324.CrossRef
51.
Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol. 2005;129(4):465–81.CrossRefPubMed
52.
53.
Akinola NO, et al. The import of abdominal pain in adults with sickle cell disorder. West Afr J Med. 2009;28(2):83–6.PubMed
54.
Ballas SK, et al. Sickle cell disease: current clinical management. Semin Hematol. 2001;38(4):307–14.CrossRefPubMed
55.
Sebastiani P, et al. Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. Am J Hematol. 2010;85(1):29–35.PubMedPubMedCentral
56.
Steinberg MH, Adewoye AH. Modifier genes and sickle cell anemia. Curr Opin Hematol. 2006;13(3):131–6.CrossRefPubMed
57.
Mayer ML, et al. Hospital resource utilization among patients with sickle cell disease. J Health Care Poor Underserved. 2003;14(1):122–35.CrossRefPubMed
58.
59.
Dabari S, et al. Severe painful vaso-occlusive crises and mortality in contemporary adult sickle cell anemia cohort study. PLoS One. 2013;8(11):e79923.
60.
Audard V, et al. Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. Nephrol Dial Transplant. 2010;25(8):2524–9.CrossRefPubMed
61.
Frei-Jones MJ, et al. Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease. Pediatr Blood Cancer. 2009;52(4):481–5.CrossRefPubMedPubMedCentral
62.
Carroll CP, et al. The course and correlates of high hospital utilization in sickle cell disease: evidence from a large, urban Medicaid managed care organization. Am J Hematol. 2009;84(10):666–70.CrossRefPubMedPubMedCentral
63.
Smith WR, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94–101.CrossRefPubMed
64.
Dampier C, et al. Vaso-occlusion in children with sickle cell disease: clinical characteristics and biologic correlates. J Pediatr Hematol Oncol. 2004;26(12):785–90.PubMed
65.
Vick LR, et al. Partial splenectomy prevents splenic sequestration crises in sickle cell disease. J Pediatr Surg. 2009;44(11):2088–91.CrossRefPubMed
66.
Halabi-Tawil M. Sickle cell leg ulcers: a frequently disabling complication and a marker of severity. Br J Dermatol. 2008;158(2):339–44.CrossRefPubMed
67.
Nolan VG, et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol. 2006;133(5):570–8.CrossRefPubMedPubMedCentral
68.
69.
Gill FM, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood. 1995;86(2):776–83.PubMed
70.
Cheng L, et al. Health related quality of life in pregeriatric patients with chronic diseases at urban, public supported clinics. Health Qual Life Outcomes. 2003;1:63.CrossRefPubMedPubMedCentral
71.
Wensing M, et al. Functional status, health problems, age and comorbidity in primary care patients. Qual Life Res. 2001;10(2):141–8.CrossRefPubMed
72.
Michelson H, et al. Multiple chronic health problems are negatively associated with health related quality of life (HRQoL) irrespective of age. Qual Life Res. 2000;9(10):1093–104.CrossRefPubMed
73.
74.
Bland AC, et al. The psychometric properties of five scoring methods applied to the script concordance test. Acad Med. 2005;80(4):395–9.CrossRefPubMed
75.
Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.CrossRefPubMed
76.
77.
78.
Dampier C, et al. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol. 2011;86(2):203–5.CrossRefPubMedPubMedCentral
79.
Levenson JL, et al. Depression and anxiety in adults with sickle cell disease: the PiSCES project. Psychosom Med. 2008;70(2):192–6.CrossRefPubMed
80.
Liu H, et al. Representativeness of the patient-reported outcomes measurement information system internet panel. J Clin Epidemiol. 2010;63(11):1169–78.CrossRefPubMedPubMedCentral
81.
Cella D, et al. Initial item banks and first wave testing of the Patient-Reported Outcomes Measurement Information System (PROMIS) network: 2005–2008. J Clin Epidemiol. 2010;63(11):1169–94.CrossRefPubMedPubMedCentral
82.
Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16(3):297–334.CrossRef
83.
Abdi H. Bonferroni and Šidák corrections for multiple comparisons, in encyclopedia of measurement and statistics. Thousand Oaks: Sage; 2007.
84.
Liang MH, et al. Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. Arthritis Rheum. 1985;28(5):542–7.CrossRefPubMed
85.
Keller SD, et al. The SF-36 Arthritis-Specific Health Index (ASHI): II. Tests of validity in four clinical trials. Med Care. 1999;37(5 Suppl):MS51–60.PubMed
86.
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Routledge; 1988.
87.
Nunnally JC. Psychometric theory. 2nd ed. New York: McGraw-Hill Book Company; 1967.
88.
Streiner DL. Starting at the beginning: an introduction to coefficient alpha and internal consistency. J Pers Assess. 2003;80(1):99–103.CrossRefPubMed
89.
Kaplan RM, Saccuzzo DP. Pscyhological testing: principles, applications and issues. Eighth ed. Belmont: Wasdworth, Cengage Learning; 2013.
90.
Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.
91.
Vichinsky E, et al. Neuropsychological dysfunction and neuroimaging adult sickle cell anemia study group. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA. 2010;303(18):1823–31.CrossRefPubMedPubMedCentral
92.
Ballas SK, et al. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. The Scientific World J. 2012. Published online 2012 Aug 1.
93.
94.
Keller S, Yang M. Disease-specific calibrations or disease-specific content: which is responsible for the enhanced sensitivity of condition-specific measures compared to generic measures? Qual Life Res. 2015;24:25.
95.
96.
Feliu MH, et al. Neurocognitive testing and functioning in adults sickle cell disease. Hemoglobin. 2011;35(5–6):476–84.CrossRefPubMed
97.
Cook KF, et al. A PROMIS fatigue short form for use by individuals who have multiple sclerosis. Qual Life Res. 2012;21(6):1021–30.CrossRefPubMed
98.
Kratz AL, et al. The PROMIS FatigueFM Profile: a self-report measure of fatigue for use in fibromyalgia. Qual Life Res. 2016;25:1803.CrossRefPubMed
99.
Choi SW. Firestar: computerized adaptive testing simulation program for polytomous item response theory models. Appl Psychol Measur. 2009;33(8):644.CrossRef
100.
Jaeschke R, et al. Measurement of health status: ascertaining the minimally clinically important difference. Cont Clin Trials. 1989;10:407–15.CrossRef
Metadata
Title
Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS® to ASCQ-Me℠
Authors
San Keller
Manshu Yang
Marsha J. Treadwell
Kathryn L. Hassell
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2017
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-017-0661-5

Other articles of this Issue 1/2017

Health and Quality of Life Outcomes 1/2017 Go to the issue

Research

Validation of the Italian version of the Laval questionnaire: health-related quality of life in subjects with obesity

Research

Bayesian nonparametric estimation of EQ-5D utilities for United States using the existing United Kingdom data

Research

Impact of 6 months of treatment with intragastric balloon on body fat and quality of life in obese individuals with metabolic syndrome

Research

Resilient coping in the general population: standardization of the brief resilient coping scale (BRCS)

Research

Developing a proxy version of the Adult social care outcome toolkit (ASCOT)

Research

Validation of the French versions of the Hirschsprung’s disease and Anorectal malformations Quality of Life (HAQL) questionnaires for adolescents and adults